OncoMatch/Clinical Trials/NCT04104776
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Is NCT04104776 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Tulmimetostat and Enzalutamide for advanced solid tumor.
Treatment: Tulmimetostat · Enzalutamide — The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid tumors and lymphomas.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Tumor Agnostic
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mesothelioma
Prostate Cancer
Endometrial Cancer
Ovarian Cancer
Biomarker criteria
Required: ARID1A mutation
Required: ARID1A mutation
Required: ARID1A mutation
Required: ARID1A wild-type
Required: BAP1 loss
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: solid organ or allogeneic hematopoietic cell transplant
Prior solid organ or allogeneic hematopoietic cell transplant
Cannot have received: EZH2 inhibitor
Prior EZH2 inhibitor treatment
Lab requirements
Blood counts
Adequate bone marrow function per protocol-defined thresholds
Kidney function
Adequate renal function per protocol-defined thresholds
Liver function
Adequate hepatic function per protocol-defined thresholds
Adequate bone marrow, renal, and hepatic function per protocol-defined thresholds
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- Emory University School of Medicine · Atlanta, Georgia
- University of Chicago · Chicago, Illinois
- Loyola University Medical Center · Maywood, Illinois
- University of Maryland Medical Ctr · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04104776 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior solid organ or allogeneic hematopoietic cell transplant, EZH2 inhibitor disqualifies patients from enrollment.
Does this trial require ARID1A?
Yes, ARID1A mutation is a required biomarker for enrollment.
Does this trial require ARID1A?
Yes, ARID1A mutation is a required biomarker for enrollment.
Does this trial require ARID1A?
Yes, ARID1A mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify